Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren 150 mg Added to Standard Therapy in Stable Heart Failure
2004-004014-16Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertension (HTN) and heart failure (HF) comparing Aliskiren 150 mg + standard therapy with Placebo + standard therapy (2 arms). Primary endpoint: Overall safety and tolerability of aliskiren 150 mg. Started Feb 2005; status: completed.
02
Drugs
aliskiren
03
Conditions
hypertension (HTN)heart failure (HF)
Beyond the preview
Go deeper on 2004-004014-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004014-16.